Apr 17, 2012 | Capital Markets, Congressional Testimony
***Media Advisory*** COMMITTEE ON CAPITAL MARKETS REGULATION’S EXECUTIVE DIRECTOR FOR RESEARCH TESTIFIES THAT SOUND COST-BENEFIT ANALYSIS “MUST BE A PART” OF RULEMAKING WASHINGTON, April 17 2012 Jacqueline C. McCabe, Executive Director for Research of the Committee on...
Apr 1, 2012 | Capital Markets, Op-Ed
By HAL SCOTT and LESLIE N. SILVERMAN Originally published by Wall Street Journal on April 1, 2012 Last month, the Securities and Exchange Commission rejected attempts by the Carlyle Group, and proposals by stockholders of Pfizer and Gannett, to mandate arbitration...
Mar 26, 2012 | Capital Markets, Letter
Re: The Jumpstart Our Business Startups Act (JOBS Act) Dear Mr. Speaker and Leader Pelosi: The Committee on Capital Markets Regulation (Committee) is writing to express our support for many of the proposals contained in the Jumpstart Our Business Startups Act (JOBS...
Mar 7, 2012 | Capital Markets, Letter
The Committee on Capital Markets Regulation today warned Congress of its “deep concern about the inadequacy of cost-benefit analysis” that its research has identified in proposed rulemaking under the Dodd-Frank, Wall Street Reform and Consumer Protection Act....
